Navigation Links
Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
Date:8/19/2007

SUNNYVALE, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it has entered into a five-year master purchase order with Northrop Grumman for the purchase of up to $200 million in Bacillus anthracis (anthrax) test cartridges and associated materials. The anthrax test is currently used in Biohazard Detection Systems (BDS), installed at United States Postal Service (USPS) mail processing centers nationwide. The agreement covers the USPS fiscal years of 2007 through 2011. Cepheid began supplying USPS with GeneXpert(R) modules and anthrax test cartridges in 2003.

Under the terms of the agreement, the purchase quantity of anthrax tests will be determined on an annual basis, based on the USPS fiscal year of October 1 through September 30. Cepheid has received notice that expected test purchases for fiscal 2008 will be approximately two million cartridges.

"This agreement is a testament to the success of the ongoing program with the USPS, in which more than 5.2 million tests have been run with no false positives," stated John Bishop, Cepheid CEO. "The achievements in the biothreat market reflect the versatility and the reliability of the GeneXpert System that is now being brought to the molecular clinical diagnostic market."

The GeneXpert modules and anthrax test cartridges serve as the foundation of the BDS system. The BDS system rapidly analyzes air samples taken from the mail sorting systems in order to detect any potential trace levels of DNA from anthrax spores as mail travels through the mail processing equipment.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the proposed purchases for the USPS BDS program, and business prospects. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially including that the maximum of $200 million may not be achieved, include risks and uncertainties such as those relating to: the rate of environmental testing using the BDS conducted by the USPS, which will affect the amount of consumable products sold; whether the BDS continues to perform to specifications; manufacturing problems, including with respect to the GeneXpert system and reagents. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2006 and "Risk Factors" in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.


'/>"/>
SOURCE Cepheid

Copyright©2007 PR Newswire.

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Wellcentive ... a Portland, Oregon -based community ... to provide population health analytics, quality reporting and ... help FamilyCare strengthen its team of quality managers, ... reporting to the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... BioInformant announces the February 2016 release of its ... and Technologies – Market Size, Segments, Trends, and Projections ... The first and only market research firm ... more than a decade of historical information on all ... type. This powerful 175 page global strategic report contains ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):